Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
Adjuvants, Immunologic
/ administration & dosage
Adolescent
Adult
Antibodies, Viral
/ immunology
B-Lymphocytes
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
Child
Cross Reactions
/ immunology
Female
Humans
Immunization Schedule
Papillomaviridae
/ immunology
Papillomavirus Infections
/ immunology
Papillomavirus Vaccines
/ immunology
Vaccination
/ methods
Young Adult
AS04-HPV-16/18 vaccine
HPV-31
HPV-45
cross-reactivity
immunogenicity
nonvaccine types
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
05 05 2019
05 05 2019
Historique:
received:
13
11
2018
accepted:
08
01
2019
pubmed:
5
2
2019
medline:
23
2
2020
entrez:
5
2
2019
Statut:
ppublish
Résumé
This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.
Identifiants
pubmed: 30715452
pii: 5306135
doi: 10.1093/infdis/jiy743
pmc: PMC6500548
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Viral
0
Papillomavirus Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT01381575', 'NCT00541970']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1799-1803Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Hum Vaccin. 2011 Dec;7(12):1359-73
pubmed: 22048172
Vaccine. 2006 Aug 14;24(33-34):5937-49
pubmed: 16828940
Lancet Oncol. 2012 Jan;13(1):89-99
pubmed: 22075171
J Infect Dis. 2017 Jun 1;215(11):1711-1719
pubmed: 28591778
J Infect Dis. 2018 Apr 23;217(10):1579-1589
pubmed: 29409034
Hum Vaccin Immunother. 2016;12(1):20-9
pubmed: 26176261
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Lancet Infect Dis. 2017 Dec;17(12):1293-1302
pubmed: 28965955
Lancet Infect Dis. 2016 Oct;16(10):1154-1168
pubmed: 27373900
J Infect Dis. 2018 Aug 14;218(6):911-921
pubmed: 29917082
Lancet Infect Dis. 2017 Dec;17(12):1227-1228
pubmed: 28965956
Wkly Epidemiol Rec. ;92(19):241-68
pubmed: 28530369
Hum Vaccin Immunother. 2014;10(5):1155-65
pubmed: 24576907